



(11) **EP 1 716 752 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
16.09.2009 Bulletin 2009/38

(51) Int Cl.:
A01K 67/027^(2006.01)

(21) Application number: **05077734.1**

(22) Date of filing: **13.01.2000**

(54) **MyoD88-knockout mouse as a model animal unresponsive to bacterial cell wall components**

MyoD-knockout Maus als Bakterienzellwandbestandteil-unansprechender Tiermodell

Souris knockout pour le gène MyD88 comme modèle insensible aux composantes des parois de cellules bactériennes

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **14.01.1999 JP 736599**
12.08.1999 JP 22828299
29.10.1999 JP 30923899

(43) Date of publication of application:
02.11.2006 Bulletin 2006/44

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
00900372.4 / 1 142 472

(73) Proprietor: **Japan Science and Technology Agency**
Kawaguchi-shi
Saitama (JP)

(72) Inventors:
• **Akira, Shizuo**
Mino-shi,
Osaka 562-0031 (JP)

• **Takeuchi, Osamu,**
Osaka University
Suita-shi,
Osaka 565-0871 (JP)
• **Takeda, Kiyoshi,**
Kyushu University
Fukuoka 812-8582 (JP)

(74) Representative: **Holliday, Louise Caroline**
D Young & Co
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
• **ADACHI O ET AL: "TARGETED DISRUPTION OF THE MYD88 GENE RESULTS IN LOSS OF IL-1- AND IL-18-MEDIATED FUNCTION" IMMUNITY, CELL PRESS, US, vol. 9, July 1998 (1998-07), pages 143-150, XP002927802 ISSN: 1074-7613**
• **TAKEUCHI O ET AL: "CELLULAR RESPONSES TO BACTERIAL CELL WALL COMPONENTS ARE MEDIATED THROUGH MYD88-DEPENDENT SIGNALING CASCADES" INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 12, no. 1, January 2000 (2000-01), pages 113-117, XP002945405 ISSN: 0953-8178**

EP 1 716 752 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

DescriptionTechnical Field

5 **[0001]** The present invention relates to uses of model non-human animals which are unresponsive to bacterial cell wall components. The bacteria cell wall component may be a lipoprotein/lipopeptide, which is a cell component of bacteria that belong to Mycoplasma, Spirochaeta, Escherichia or the like. The bacterial cell wall component may be a peptidoglycan, which is a cell wall fraction of Gram-positive bacteria. Alternatively the bacterial cell wall component may be endotoxin, which is a cell wall fraction of Gram-negative bacteria.

Background Art

15 **[0002]** Cytokines are intracellular signal transmitters which play an important role in an immune response, a response upon infection, hematopoiesis, inhibition of virus infection and tumor cells. Among them, a cytokine which transmits signals between lymphocytes is called interleukin (hereinafter, "IL"). Among ILs, IL-1 is a cytokine which mediates various immune responses and inflammatory responses, and is involved in maintenance of homeostasis of living organisms and produced from various cells such as monocytes, macrophages, keratinocytes, vascular endothelial cells and the like when the living organisms get infected or hurt. It has been known that there are two kinds of IL-1, IL-1 α and IL-1 β , both of which combine to the same receptor. It has been also known that IL-1 exerts its function simultaneously with the activation by an antigen to T cell and by mitogens, makes T cells release IL-2, and enhances the expression of IL-2 receptors to induce T cell proliferation, and that it acts on monocytes and macrophages in order to induce the production of TNF- α , IL-1, IL-6.

20 **[0003]** IL-1 has two kinds of IL-1 receptors (hereinafter "IL-1R"), and both of the IL-1Rs, type I and type II, have three immunoglobulin-like domains in their extracellular domains. Type I receptors express in T cells and connective tissue, and type II receptors express in splenic B cells, myeloids and the like, and it has been known that type I receptors induce NF- κ B in nuclei. It has been also known that there is an IL-1 receptor antagonist (hereinafter "IL-1ra") which shows no bioactivity in spite that it binds to IL-1R with the affinity similar to that of IL-1 α and IL-1 β , and that it prevents IL-1 from binding to IL-1R competitively.

25 **[0004]** IL-18 is known to promote the production of interferon- γ (hereinafter "IFN- γ "), to enhance the activation of natural killer cells, to induce the production of IFN- γ from T cells in cooperation of IL-12, and to act an important role in a Th1 (IL-2 producing helper T cells) response. Further, it is known that IL-18 has no structural similarity to IL-12 in spite that it has a functional similarity, and has a structural similarity to IL-1. Moreover, it has been also known that IL-18 is produced as an inactive precursor that requires cleavage by IL-1 β -converting enzyme (ICE)/caspase1 for its maturation, as in the case of IL-1 β , and that IL-18 activates IL-1R-associated kinase (IRAK) and NF- κ B.

30 **[0005]** A plurality of molecules showing homology to IL-1R have been identified so far, and signal pathways mediated by IL-1R family is being studied intensively now. It has been known that MyD88 is a cytoplasmic protein comprised of an IL-1R homologous domain and a Death domain, and functions as an adaptor molecule which activates NF- κ B by recruiting IRAK to IL-1R complex after IL-1 stimulation, and that MyD88 gene was originally separated as a myeloid differentiation primary response gene, which rapidly induces M1 myeloleukemic cells to macrophages by IL-6-stimulated differentiation.

35 **[0006]** Toxins in bacterial cells being comprised of lipopolysaccharide, which is a major structural component of the outer membrane encompassing peptidoglycan on the surface of Gram-negative bacteria, are called endotoxin, and it has been known that lipopolysaccharide is comprised of lipid called lipid A and various kinds of saccharide which covalently bind to the lipid A. It has been also known that this endotoxin has a bioactivity mainly involved in fever, decrease of leukocytes and platelet, hemorrhagic necrosis of bone marrow cells, hypoglycemia, induction of IFN, activation of B lymphocyte (immune response cell derived from marrow), and the like.

40 **[0007]** It has been known that a Toll gene is required to control dorsoventral patterning during the embryonic development of Drosophila (Cell 52, 269-279, 1988, Annu. Rev. Cell Dev. Biol. 12, 393-416, 1996), and for antifungal immune responses in adult fly (Cell 86, 973-983, 1996). It has been clarified that the Toll is a type I transmembrane receptor with an extracellular domain containing leucine-rich repeat (LRR) and that its cytoplasmic domain shows high homology to that of mammalian interleukin-1 receptor (IL-1R)(Nature 351, 355-356, 1991, Annu. Rev. Cell Dev. Biol. 12, 393-416, 1996, J. Leukoc. Biol. 63, 650-657, 1998). It has been also clarified that another Toll family member, 18-wheeler, participates in the antibacterial host defense but not in the antifungal immune response, and that particular pathogens induce specific antimicrobial immune responses in Drosophila through the selective activation of the Toll pathways (Proc. Natl. Acad. Sci. USA 94, 14614-14619, 1997, EMBO J. 16, 6120-6130, 1997, Curr. Opin. Immunol. 11, 13-18, 1999).

45 **[0008]** Recently, mammalian homologs of Toll, designated as Toll-like receptors (TLRs), have been identified, and so far, six families including TLR2 and TLR4 have been reported (Nature 388, 394-397, 1997, Proc. Natl. Acad. Sci. USA 95, 588-593, 1998, Blood 91, 4020-4027, 1998, Gene 231, 59-65, 1999). It has been known that the TLR families, as

in the case of the IL-1R, recruit IL-1R-associated kinase (IRAK) through the adaptor protein MyD88 as a signal transmitter and activate TRAF 6, and then activate NF- κ B in the downstream (J. Exp. Med. 187, 2097-2101, 1998, Mol. Cell 2, 253-258, 1998, Immunity 11, 115-122, 1999). Further, the role of the TLR families in mammals is also believed to participate in innate immune recognition as pattern recognition receptors (PRRs), which recognize bacterial cell common structures (Cell 91, 295-298, 1997).

[0009] It has been reported that one of such pathogen-associated molecular patterns (PAMPs) to be recognized by the PRRs is lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria (Cell 91, 295-298, 1997), that said LPS stimulates host cells and makes them produce various proinflammatory cytokines including TNF- α , IL-1, and IL-6 (Adv. Immunol. 28, 293-450, 1979, Annu. Rev. Immunol. 13, 437-457, 1995), and that the LPS captured by LPS-binding protein (LBP) is delivered to CD14 on the cell surface (Science 249, 1431-1433, 1990, Annu. Rev. Immunol. 13, 437-457, 1995). However, since CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein without a transmembrane domain, the existence of a bona fide signaling receptor of LPS has been believed.

[0010] TLR4, which belongs to the TLR family, is a signaling molecule of LPS, which is a bacterial cell component of Gram-negative bacteria, and transfection of the TLR4 leads to a low constitutive activation of NF- κ B (J. Exp. Med. 188, 2091-2097, 1998, Nature 395, 284-288, 1998). On the other hand, as TLR2 transmits LPS signal when overexpressed in human embryonic kidney 293 cells in vitro, TLR2 has been thought to be a candidate for the LPS receptor. In addition, Godawski's group has reported that human TLR2 could interact with CD14 to form the LPS receptor complex (J. Immunol. 163; 639-643, 1999). Stimulation treatment with LPS leads to oligomerization of receptors and to subsequent recruitment of IRAK to the receptor complex. In contrast, groups of Poltorak and Qureshi have reported that TLR4 is the causative gene of the LPS hyporesponsiveness of C3H/HeJ mice, that is, the *Lps* gene, according to positional cloning (Science 282, 2085-2088, 1998, J. Exp. Med. 189, 615-625, 1999).

[0011] The inventors of the present invention have found by generation of TLR4-deficient mice that TLR4 is actually involved in LPS signaling (J. Immunol. 162, 3749-3752, 1999). The findings may be attributed to species-specific differences in the primary structure of TLR, in other words, LPS signaling could be mediated by TLR4 in mice and by TLR2 in humans. However, there is a report showing that mouse TLR2 also activated NF- κ B in response to LPS (J. Immunol. 162, 6971-6975, 1999). In addition, Chow et al. have reported that they obtained the result showing that human TLR4 activated NF- κ B-mediated gene expression by stimulation to LPS/CD14 in a dose-dependent or a time-dependent manner, which is consistent with the observation of C3H/HeJ mice, whereas they obtained the result conflicting with that of Kirschning's group when human 293 cells were used, and they have speculated that the differences of outcome may be due to differences in the lot of 293 cells as well (J. Biol. Chem. 274, 10689-10692, 1999).

[0012] Recently, it has been reported that TLR2 may not be involved exclusively in responsiveness to LPS derived from Gram-negative bacteria (J. Immunol. 162, 6971-6975, 1999) but may also act as a signaling receptor for peptidoglycan (PGN) and lipoteichoic acid (LTA) from Gram-positive bacteria, which have another common bacterial structural pattern (J. Biol. Chem. 274, 17406-17409, 1999, J. Immunol. 163, 1-5, 1999). Further, it has been also reported that whole Gram-positive bacteria, soluble PGN, and LTA induced the activation of NF- κ B in 293 cells expressing TLR2, but not induced the activation of NF- κ B in the cells expressing TLR1 or TLR4 (J. Biol. Chem. 274, 17406-17409, 1999). Still further, it has been also reported that Chinese hamster ovary (CHO) fibroblast cells which express human TLR2 but not TLR4 were activated similarly by heat-killed *Staphylococcus aureus* and *Streptococcus pneumoniae*, and PGN derived from *Staphylococcus aureus* (J. Immunol. 163, 1-5, 1999).

[0013] Mycoplasmas, known as pathogens in animals and humans, are wall-less bacteria, yet they are capable of activating macrophages. A number of reports have identified this macrophage-activating material as lipoproteins/lipopeptides, and one of these lipopeptides, the 2kD macrophage-activating lipopeptide MALP-2 derived from *Mycoplasma fermentans*, was biochemically fully characterized and has become available by synthesis (J. Exp. Med. 185:1951, 1997). It is known that the lipid moiety has 2 asymmetric C atoms, and that the synthetic MALP-2 comprised of the S, R racemate had a specific activation similar to the natural compound action at picomolar concentrations in vitro. Little is known about the signal pathways or the cell-surface receptors for MALP-2, except that MALP-2 activates NF- κ B.

[0014] It is reported that lipoproteins/lipopeptides from mycobacterium and *Borrelia burgdorferi* induced the activation of host cells through TLR2 in vitro (Science 285, 736-739, 1999, Science 285, 732-736, 1999). Nevertheless, the conclusions obtained from overexpression experiments do not necessarily reflect the function of TLR family in vivo. It is also reported that the results of analysis of the responsiveness based on NF- κ B activation are not related to biological responses mediated by these stimuli (Infect. Immun. 66, 1638-1647, 1998).

[0015] In addition, it is known that the function of a specific gene can be analyzed in individual level by using transgenic mice in which genes are artificially introduced and expressed, and gene-deficient mice generated by gene targeting in which specific genes on genomes are artificially transformed by homologous recombination with embryonic stem cells (hereinafter "ES cells"). In general, gene-deficient mice are called knockout mice, and TLR2 knockout mice and MyD88 knockout mice have not been known, and moreover, it has not been known that TLR2 knockout mice and MyD88 knockout mice are unresponsive to bacterial cell components, either.

Summary of the Invention

5 [0016] Though in vivo responses to bacterial cell components are expected to vary depending on the difference of expression levels of each TLR on the cell surface, the contribution of individual members of the TLR family and MyD88, the adaptor protein of the TLR family, to signaling by bacterial cell components' stimuli in vivo remains to be elucidated. An object of the present invention is to provide the use of a non-human animal whose function of MyD88 gene is deficient on its chromosome as a model animal unresponsive to bacterial cell wall components. Such animals are useful for elucidating the contribution of MyD88, the adaptor protein of the TLR family; to signaling by bacterial cell components' stimuli in vivo, in particular, the role of MyD88 in vivo.

10 [0017] The inventors of the present invention have conducted intensive study for attaining the object. They generated MyD88 gene-deficient mice as follows: an exon region including two-exon regions encoding the C-terminal portion of MyD88 are replaced with the neomycin-resistant gene respectively by homologous recombination with plasmid vectors in ES cells and HSV-tk gene was induced into each C-terminal side respectively, and ES cell clones doubly resistant of G418 and gancyclovir were screened; the ES cell clones were microinjected into blastocysts of C57BL/6 mice; MyD88 knockout mice whose function of MyD88 gene is deficient on their chromosomes were born through the germline at the expected Mendelian ratios. Then the inventors have found that those MyD knockout mice are transgenic mice which grow healthy and show no obvious abnormalities until 20 weeks of age, and that those MyD knockout mice are unresponsive to peptidoglycan, which is a cell wall component of Gram-positive bacteria and to a lipoprotein/lipopeptide and other such bacterial cell components, and the present invention has thus completed.

20 [0018] The present invention relates to the use of a non-human animal whose function of MyD88 gene is deficient on its chromosome as a model animal unresponsive to bacterial cell wall components (claim 1). The non-human animal may be a rodent (claim 2), or a mouse (claim 3).

[0019] The present invention also relates to the use of a macrophage or splenocyte cell derived from a non-human animal as defined in any of claims 1 to 3 as a model cell unresponsive to bacterial cell wall components (claim 4).

25 [0020] The present invention may be used to elucidate the action mechanisms of bacterial cell components (claim 5).

[0021] The present invention may be used to obtain information of signalling receptors of bacterial cell wall components (claim 6).

30 [0022] The present invention may be used in a method of detecting bacterial cell components, which method comprises the steps of: (i) administering the subject material to a) an animal or cell as defined in any of claims 1 to 4 and b) to a wild-type non-human animal or cell and (ii) assessing and comparing responsiveness to the subject material (claim 7).

[0023] The present invention may be used to obtain information for development of medicines for diseases caused by excessive production of bacterial cell wall components (claim 8).

35 [0024] In connection with the use of the present invention, the bacterial cell wall component is a lipoprotein/lipopeptide (claim 9). The lipoprotein/lipopeptide may, for example be derived from cell components of bacteria which belong to Mycoplasma, Spirochaeta or Escherichia (claim 10).

[0025] In connection with the use of the present invention the bacterial cell wall component is a peptidoglycan (claim 11), an endotoxin (claim 12), lipotechoic acid (claim 13) or Mycobacterium tuberculosis lysate (claim 14).

[0026] The present invention may be used to establish a treatment method for endotoxin shock (claim 15).

40 [0027] The present invention may be used to elucidate the molecular mechanism in a process of infection by bacteria to the cell wall components of which the animal is unresponsive (claim 16).

[0028] The present invention may be used to develop new remedies for infection by bacteria to the cell wall components of which the animal is unresponsive (claim 17).

Brief Explanation of Drawings

45 [0029]

Fig. 1 is a graph showing gene maps of MyD88 knockout mice and wild-type mice.

50 Fig. 2 is a graph showing survival indices of MyD88 knockout mice and wild-type mice having an injection of LPS derived from Escherichia coli.

Fig. 3 is a graph showing the results of T cell proliferation mediated by IL-1 in MyD88 knockout mice and wild-type mice .

Fig. 4 is a graph showing the results of IL-1-induced TNF- α and IL-6 levels in blood in MyD88 knockout mice and wild-type mice.

55 Fig. 5 is a graph showing the results of NK cell activation mediated by IL-18 in MyD88 knockout mice and wild-type mice.

Fig. 6 is a graph showing the results of the production of IFN- γ stimulated by IL-12 and IL-18 in MyD88 knockout mice and wild-type mice.

Fig. 7 is a graph showing that the mutation of dominant negative MyD88 is involved in IL-18-induced NF- κ B activity and AP-1 activity.

Fig. 8 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to *Salmonella minnesota* Re-595.

Fig. 9 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to IL-4 and interferon- γ .

Fig. 10 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to *Porphyromonas gingivalis*.

Fig. 11 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to *Escherichia coli* 055:B5.

Fig. 12 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to peptidoglycan.

Fig. 13 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to lipoteichoic acid.

Fig. 14 is a graph showing the results of responsiveness of macrophages and splenic B cells of MyD88 knockout mice, wild-type mice and TLR4 knockout mice to whole cell lysates of *Mycobacterium tuberculosis*.

Fig. 15 is a graph showing gene maps of TLR2 knockout mice and wild-type mice.

Fig. 16 is a graph showing survival indices of TLR2 knockout mice and wild-type mice having an injection of LPS derived from *Escherichia coli*.

Fig. 17 is a graph showing lipid A- or LPS-induced production amount of IL-6, TNF- α or NO₂⁻ in TLR2 knockout mice, wild-type mice and TLR4 knockout mice.

Fig. 18 is a graph showing the results of responsiveness of splenic B cells of TLR2 knockout mice, wild-type mice and TLR4 knockout mice to LPS derived from *Salmonella minnesota* Re-595.

Fig. 19 is a graph showing the results of responsiveness of peritoneal macrophages of TLR2 knockout mice, wild-type mice and TLR4 knockout mice to cell wall fractions of Gram-positive bacteria.

Fig. 20 is a graph showing PGN- or LTA-induced production amount of IL-6, NO₂⁻ or TNF- in TLR2 knockout mice, wild-type mice and TLR4 knockout mice.

Fig. 21 is a graph showing the results of LPS- or PGN-stimulated in vitro kinase assay, Western blot analysis and electrophoretic mobility shift assay in TLR2 knockout mice, wild-type mice and TLR4 knockout mice.

Fig. 22 is a graph showing the results of responsiveness of peritoneal macrophages of CH3/HeJ mice to lipopeptide MALP-2.

Fig. 23 is a graph showing the results of responsiveness of human monocytes to lipopeptide MALP-2.

Fig. 24 is a graph showing the results of responsiveness of peritoneal macrophages of TLR2 knockout mice, wild-type mice, TLR4 knockout mice and MyD88 knockout mice to lipopeptide MALP-2.

Fig. 25 is a graph showing the results of lipopeptide MALP-2-stimulated in vitro kinase assay, Western blot analysis and electrophoretic mobility shift assay in TLR2 knockout mice, wild-type mice, TLR4 knockout mice and MyD88 knockout mice.

Best Mode for Carrying out the Invention

[0030] Examples of bacterial cell components include: a lipoprotein/lipopeptide, which is a cell component of bacteria which belong to *Mycoplasma*, *Spirochaeta*, *Escherichia*; peptidoglycan comprised by combining repeating polysaccharides of N-acetylglucosamine and N-acetylmuramic acid, which is a skeletal structure of bacterial cell wall, and relatively short peptide chain; lipopolysaccharide (LPS) which exists mainly as an outer membrane component of Gram-negative bacteria and is also called endotoxin; lipoteichoic acid (LTA), which is a cell wall component of Gram-positive bacteria; *Mycobacterium tuberculosis* lysate; and a cell wall fraction of Gram-positive bacteria. Further, in connection with the present invention, carriers which carry the above mentioned bacterial cell components, and the bacterial cell themselves are expediently included in the examples of the bacterial cell components.

[0031] In connection with the present invention, "unresponsiveness to bacterial cell components" means that the non-human animals, or cells, tissue, or organs derived therefrom show low reactivity or almost no reactivity to the stimuli of the bacterial cell components, and "hyporesponsiveness" means low reactivity to the stimuli. Therefore, a model non-human animal being unresponsive to bacterial cell components in connection with the present invention means a non-human animal such as a mouse, a rat, a rabbit or the like, where living organisms, or cells, tissue, or organs which comprise living organisms show low reactivity or almost no reactivity to the stimuli of the bacterial cell components. Examples of the stimuli of the bacterial cell components include an in vivo stimulus where a bacterial cell component is administered to a living organism and an in vitro stimulus where a bacterial cell component is brought into contact with cells separated from a living organism. As an example of a model non-human animal being unresponsive to bacterial cell components, a non-human animal unresponsive to bacterial cell components such as a lipoprotein/lipopeptide, pepti-

doglycan, a cell wall fraction of Gram-positive bacteria, endotoxin, lipoteichoic acid, Mycobacterium tuberculosis lysate and the like is exemplified, and specifically, a non-human animal whose function of MyD88 gene is deficient on its chromosome, such as a MyD88 knockout mouse and the like are exemplified.

[0032] In connection with the present invention, "deficiency of MyD88 gene function on a chromosome" means that a part of or a whole of MyD88 gene on a chromosome is deficient and the function to express MyD88, which is expressed in wild-types, is lost. Examples of a non-human animal whose function of MyD88 gene is deficient on its chromosome include a rodent such as a rat or the like whose function of MyD88 gene is deficient other than MyD88 knockout mice.

[0033] The term "a wild-type non-human animal" in connection with the present invention means a non-human animal being the same species of the non-human animal whose function of MyD88 gene is deficient on its chromosome. For example, in case of mice, it means MyD88-nondeficient type mice of same species among F2 mice generated at the expected Mendelian ratio. When the deficient type and the wild-type mice of these F2 mice, in particular, the wild-type littermates are used for experiments simultaneously, it becomes possible to conduct precise comparative experiments at individual level. With an example of knockout mice which have deficiency in MyD88, a generating method of the non-human animal whose function of MyD88 gene is deficient on its chromosome will now be explained.

[0034] MyD88 gene can be cloned by amplifying a mouse genomic library by PCR or other methods with a probe derived from a mouse EST clone or the like. By DNA recombination technique a part of or a whole of this cloned MyD88 gene, for example, a part or a whole of an exon region containing a cytoplasmic region of MyD88 gene is replaced with a poly A signal and a marker gene such as a neomycin resistance gene or the like, a targeting vector is constructed by inducing genes such as diphtheria toxin A fragment (DT-A) gene or herpes simplex thymidine kinase (HSV-tk) gene or the like into 5'-terminal side, this constructed targeting vector is linearized, and introduced into embryonic stem cells (ES cells) by electroporation method or the like, then cultured, and subsequently ES cells achieving homologous recombination by G418, ganciclovir (GANC) or other such antibiotics are selected. It is preferable to confirm whether these selected ES cells are the object recombinants by Southern blot analysis or the like.

[0035] Chimeric mice can be obtained by microinjecting the recombined ES cells into blastocysts of mice, and put the blastocysts back into uteri of recipient mice. Under high chimeric ratio, there will be born much more male chimeric mice than female ones. In such case, heterologous recombinant mice (+/-: F1) are generated by intercrossing the chimeric mice with female wild-type mice, and the homologous recombinant mice [F2; wild-type mice (+/+), MyD88 knockout mice (-/-)] can be obtained by mating the heterologous recombinant male mice and female mice. All of these mice are generated at the expected Mendelian ratio. As the method of confirming whether MyD88 knockout mice of the present invention are born, for example, the method wherein RNA is isolated from peritoneal macrophages of mice obtained by the above-stated method, and is examined by Northern blot analysis or the like, and the method wherein the expression of MyD88 in the mice is examined by Western blot analysis or the like are exemplified.

[0036] It is possible to confirm that the generated MyD88 knockout mice are unresponsive to cell wall components of bacteria, for example, by contacting a lipoprotein/lipopeptide, which is a cell component of bacteria which belong to Mycoplasma, Spirochaeta, Escherichia or the like with macrophages of MyD88 knockout mice or human monocytes in vitro, and then measuring the production amount of TNF- α or NO₂⁻ in the cells; by injecting LPS, which is a cell wall component of Gram-negative bacteria into MyD88 knockout mice by intravenous injection or the like, and then measuring bioactivity of endotoxin such as fever, shock, decrease of leukocytes or platelet, hemorrhagic necrosis of bone marrow cells, hypoglycemia, induction of IFN, activation of B lymphocyte (immune response cell derived from marrow) or the like; by measuring the induction of IFN, proliferative response of splenic B cells, the expression of MHC class II antigen on the surface of splenic B cells, in macrophages or splenic B cells of MyD88 knockout mice, in the presence of LPS derived from bacteria, or peptidoglycan, which is a cell component of Gram-negative bacteria, lipoteichoic acid, Mycobacterium tuberculosis lysate or the like.

[0037] The MyD88 knockout mice used in the present invention are unresponsive to a lipoprotein/lipopeptide, which is a bacterial cell component, and show lower responsiveness to endotoxin than C3H/HeJ mice, which have been known as being hyporesponsive to endotoxin so far, and no shock symptom has been observed. Moreover, macrophages and splenic B cells of MyD88 knockout mice are unresponsive not only to endotoxin but also to peptidoglycan being a cell wall component of Gram-positive bacteria, lipoteichoic acid, Mycobacterium tuberculosis lysate and the like, while they are responsive to IL-4 and IFN-. Therefore, the knockout mice being unresponsive to bacterial cell components can be used as useful model for elucidating action mechanisms of a lipoprotein/lipopeptide, endotoxin, peptidoglycan, lipoteichoic acid or the like, and for establishing a treatment method for endotoxin shock.

[0038] The present invention provides the use of a macrophage or splenocyte cell derived from a non-human animal whose function of MyD88 is deficient on its chromosome as a model cell unresponsive to bacterial cell wall components.

[0039] As a method of measuring and assessing the macrophage activity level, the method of measuring and assessing the production amount of cytokine and/or nitrous ion in the macrophage is exemplified, and as a method of measuring and assessing the splenocyte activity level, a method of measuring and assessing the expression amount of MHC class II in the splenocyte is exemplified. In the measurement and the assessment of the macrophage activity level or the splenocyte activity level, it is preferable to assess the levels in comparison to the measured value of a wild type non-

human animal, in particular, a littermate wild type non-human animal of the non-human animal being unresponsive to bacterial cell components as control, because there will be no dispersion caused by individual differences. This can be applied to the assessment of bioactivity of various subject materials and detection of bacterial cell components and the like, in which the non-human animal being unresponsive to bacterial cell components is used.

[0040] The relationship between IL-1 and the illness in disease model mice can be examined by precisely assessing IL-1 activity of a subject material with MyD88 knockout mice. It becomes possible to obtain useful information for developing pharmaceuticals which can cure diseases such as rheumatoid arthritis caused by overexpression of IL-1, a graft-versus-host disease, asthma and the like by precisely assessing IL-1 activity of a subject material and by analyzing the involvement of IL-1 in disease model mice. Examples of IL-1 activity as an object of assessment include mitogens such as phytohemagglutinin (PHA), concanavalin A (Con A) and the like, proliferation inducing activity of T cells caused by co-stimulation with IL-2 at a low concentration, and activity which induces the production of TNF- α , IL-1 and IL-6 by working on monocytes and macrophages.

[0041] Moreover, by precisely assessing IL-1 activity of a subject material with MyD88 knockout mice, it becomes possible to obtain useful information for developing pharmaceuticals which can cure diseases caused by overproduction of IL-18, such as I type diabetes, a graft-versus-host disease and the like. Examples of IL-18 activity as an object of assessment include activity which promotes production of IFN- γ , activity which enhances activity of NK cells, activity which induces production of IFN- γ from T cells in cooperation with IL-12, and action which activates IRAK or NF- κ B.

[0042] The present invention provides the use of a non-human animal whose function of MYD88 is deficient on its chromosome, in a method of detecting bacterial cell components, which method comprises the steps of: (i) administering the subject material to a) an animal whose function of MYD88 is deficient on its chromosome, or cell derived therefrom and b) to a wild-type non-human animal or cell and (ii) assessing and comparing responsiveness to the subject material.

[0043] With the method of detecting the bacterial cell components, it is possible to detect insubstantial amount of bacterial cell components contained in subject materials in the non-human animal being unresponsive to bacterial cell components after the subject material has been administered to the non-human animal. The examples of such bacterial cell components include; a lipoprotein/lipopeptide derived from a cell component of bacteria which belong to Mycoplasma, Spirochaeta, Escherichia and the like; endotoxin derived from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Serratia marcescens, Shigella flexneri, Vibrio cholerae, Salmonella minnesota, Porphyromonas gingivalis and the like; peptidoglycan derived from Staphylococcus aureus, Corynebacterium diphtheriae, Nocardia coeliaca and the like; lipoteichoic acid derived from Streptococcus pneumoniae and the like; and whole cell lysates of Mycobacterium tuberculosis.

[0044] The present invention will be explained more specifically with examples below, but the technological scope of the present invention is not limited to these examples.

Example 1 (Generation of MyD88 knockout mice)

[0045] A MyD88 gene was screened from a 129/SvJ mouse genomic library (Stratagene), subcloned into pBluescript vector (Stratagene), and characterized by restriction enzyme mapping and DNA sequencing. A targeting vector was constructed by replacing the 1.0 kb genomic fragment of the wild-type allele with a neomycin resistance gene from pMC1-neo (Stratagene). The replaced genomic fragment contained 2 exons encoding the domain that resembles the cytoplasmic domain of the IL-1RAcP (receptor accessory protein). The neomycin resistance gene was flanked by the 1.1 kb 5' genomic fragment and the 5.2 kb 3' fragment. Then, an HSV-tk cassette was introduced into the 3' end of the genomic fragment. E14.1 ES cells were transfected with the linearized targeting vector and selected with G418 and gancyclovir. Doubly resistant 176 clones were screened for homologous recombination by PCR and 33 clones were verified by Southern blot analysis using the probe indicated in Fig. 1.

[0046] Three independently identified targeted ES clones were microinjected into the blastocysts of C57BL/6 mice. Thus obtained chimeric mice were mated with C57BL/6 female mice to produce heterozygous mice. The Heterozygous mice were intercrossed to obtain homozygotes, and MyD88-deficient were born at the expected Mendelian ratios (+/+ : +/- : -/- = 52:93:53) from the intercross. The MyD88 knockout mice of the present invention grew healthy and showed no obvious abnormalities until 20 weeks of age. Northern blot analysis was performed to confirm that the inactivation of the MyD88 gene was caused by mutation. MyD88 mRNA could not be detected in the liver and the spleen of the MyD88-deficient mice. Flow cytometric analysis of CD3, B220, CD4, and CD8 in thymus, spleen, and lymph node showed that lymphocyte composition was not altered in the MyD88 knockout mice in comparison with wild-type mice.

Example 2 (Unresponsiveness of MyD88 knockout mice to Endotoxin)

[0047] 1mg of LPS derived from Escherichia coli (055:B5) was administered to 10 MyD88 knockout mice of the present invention, and endotoxin-unresponsiveness was examined through the survival ratio of the mice. 10 wild-type littermates were used as control. The results are shown in Fig. 2. It is confirmed by Fig. 2 that though the wild-type mice have

responded to LPS and all of them died within 4 days after administration, none of the MyD88 knockout mice have died within 4 days after LPS administration, and that the mice are endotoxin-unresponsive.

Example 3 (Impaired IL-1-mediated functions in MyD88 knockout mice)

[0048] 1×10^5 of thymocytes of the MyD88 knockout mice were cultured in 96-well plates for 72 hours with mixtures containing 2 $\mu\text{g/ml}$ of phytohemagglutinin (PHA), which is a costimulant of IL-1 for T cell proliferation, 2.5 $\mu\text{g/ml}$ of concanavalin A (ConA), or 2 ng/ml of IL-2 respectively, and 100 U/ml of IL-1 β (Genzyme), and T cells were proliferated. Proliferation of T cells were examined by measuring [^3H] amount of [^3H] thymidine taken into the cells. As a result, thymocytes of wild-type littermates displayed enhanced proliferation when cultured with PHA, ConA or IL-2 in the presence of IL- β , however, thymocytes of the MyD88 knockout mice show almost no enhanced proliferation (see Fig. 3). It has been found that similar results could be obtained even when splenic B cells were used instead of thymocytes.

[0049] Further, thymocytes of MyD88 knockout mice were cultured with 10 ng/ml of phorbol 12-myristate 13-acetate paramethoxyamphetamine (PMA) or 2.5 $\mu\text{g/ml}$ of Con A in the presence of 20 ng/ml of IL-2 (Genzyme) in a same manner as above-mentioned, and enhancement of proliferation was examined. There was no difference between thymocytes of MyD88 knockout mice and of wild-type littermates in their proliferation as to the reaction of IL-2 and PMA or Con A (see Fig. 3). These results indicate that IL-1-mediated growth signal of T cells was impaired in the thymocytes of MyD88 knockout mice.

[0050] MyD88 knockout mice were intravenously injected with 1 pg of IL- β (Genzyme), and 2 hours later liver and sera were taken. Total RNA was extracted from the liver using Trizol reagent (GIBCO). This RNA (10 μg) was electrophoresed and transferred to a nylon membrane, then Northern blot analysis was conducted with ^{32}P -labelled cDNA for acute phase proteins such as serum amyloid A (SAA-I), serum amyloid P(SAP), and haptoglobin (HP). In comparing IL-1-induced increase of mRNA expression in wild-type littermates and in MyD88 knockout mice, increase of induction was observed in wild-type mice, but not observed in MyD88 knockout mice.

[0051] Because IL-1 induces production of acute phase proteins such as tumor necrosis factor (TNF- α) or IL-6, and proinflammatory cytokines, increase of TNF- α and IL-6 concentrations in serum taken from MyD88 knockout mice of the present invention and wild-type littermates by the above-stated method were measured by ELISA. As a result, TNF- α and IL-6 concentrations increased by IL-1 β in wild-type mice, while neither TNF- α nor IL-6 concentration increased by IL-1 β in MyD88 knockout mice (see Fig.4).

[0052] Thus, IL-1-mediated major biological functions has been found to be severely impaired in MyD88 knockout mice.

Example 4 (Impaired IL-18-mediated functions in MyD88 knockout mice)

[0053] It has been well known that IL-18 enhances lytic activity of NK cells. Splenic B cells from MyD88 knockout mice and wild-type littermates were cultured in the presence or absence of 20 ng/ml of IL-18 (Hayashibara Biochemical Laboratories, Inc.) for 24 hours with ^{51}Cr -labelled mouse lymphoma cells (hereinafter "YAC-1") targeting cells. 4 hours later, released ^{51}Cr in supernatants were counted by a gamma counter. As a result, when splenic B cells were cultured in the presence of IL-18 in vitro, lytic activity to YAC-1 targeting cells was dramatically enhanced in wild-type mice, but it was not enhanced in MyD88 knockout mice. When IL-2 was used instead of IL-18, lytic activity was also enhanced in splenic B cells of MyD88 knockout mice (see Fig.5).

[0054] Further, splenic B cells of MyD88 knockout mice and their wild-type littermates were stimulated by 20 ng/ml of IL-18 and cultured for 24 hours in vitro, then production of IFN- γ in culture supernatants was measured by ELISA. As a result, production of IFN- γ was induced in wild-type mice, however, production of IFN- γ was not observed in MyD88 knockout mice (see Fig.5).

[0055] Splenic T cells of MyD88 knockout mice and their wild-type littermates, which were purified to 95% or over, were cultured on anti-CD3 antibody (20 $\mu\text{g/ml}$)(PharMingen)-coated plates in the presence of 2 ng/ml IL-12. 4 days after the onset of culture; cells were harvested and washed with Hanks' balanced salt solution. The washed cells (2×10^5) were stimulated and cultured again on anti-CD3 antibody (20 $\mu\text{g/ml}$)-coated 96-well plates for 24 hours with 20 ng/ml of IL-18 or 2 ng/ml of IL-12. Concentration of IFN- γ in culture supernatants was determined by ELISA and compared. The result indicates that Splenic T cells of MyD88 knockout mice cannot enhance IL-18-responsive production of IFN- γ (see Fig.6).

[0056] MyD88 knockout mice and their wild-type littermates were intraperitoneally injected with 500 μg of heat-killed *Propionibacterium acnes* (*P. acnes*). Seven days after injection, T cells were purified from spleen, then cultured and stimulated on anti-CD3 antibody (20 $\mu\text{g/ml}$)-coated 96-well plates for 24 hours in the presence or the absence of 20 ng/ml of IL-18. Concentration of IFN- γ in culture supernatants was determined by ELISA. MyD88 knockout mice and their wild-type littermates were intravenously injected with 2 mg of *Bacillus Calmette-Guérin* (BCG) (Kyowa). 14 days after injection, T cells were purified from spleen, then cultured and stimulated for 24 hours, as described above, subsequently concentration of IFN- γ was measured. As a result, in both cases, high level of IFN- γ production in response to

IL-18 was observed in wild-type mice, but production level of IFN- γ could not be enhanced in the presence of IL-18 in MyD88 knockout mice of the present invention (see Fig.6).

[0057] These results demonstrate that MyD88 knockout mice are defective in Th1 cell development in vivo as is the case with IL-18-deficient mice, and that their major biological activities mediated by IL-18 were completely abolished.

[0058] Next, it was examined whether the dominant negative MyD88 mutant blocked IL-18-induced NF- κ B activation as well. COS-7 cells were transiently transfected with MyD88 (amino acid 152-296) expression vector together with NF- κ B-dependent luciferase reporter gene, and luciferase activity after IL-18 treatment was measured. Coexpression of MyD88 blocked IL-18-induced activation almost completely (see Fig. 7).

[0059] Because IL-18 activates AP-1-dependent gene information, whether MyD88 (amino acid 152-296) also acted as a dominant negative mutant of IL-18-induced AP-1 activation was investigated. Stimulation with IL-18 induced an approximately 3- to 4-fold increase in AP-1 activity, and this activation was blocked by coexpression of MyD88 (amino acid 152-296) (see Fig. 7). These results show that MyD88 is involved in IL-18-induced activation of both NF- κ B and AP-1.

[0060] Further, whether IL-18-induced activation of NF- κ B was observed in MyD88-deficient cells was examined. Splenic T cells cultured in the presence of IL-12 and anti-CD3 antibody for 4 days were starved for 3 hours and then stimulated with IL-18. Nuclei extracted from the stimulated cells were analyzed by a gel mobility shift assay using a specific probe containing NF- κ B binding site. IL-18-induced NF- κ B DNA binding activity was detected in the nuclear extracts from wild-type cells but not from MyD88-deficient cells. On the other hand, treatment of wild-type or MyD88-deficient thymocytes with TNF- α resulted in almost the same levels of NF- κ B DNA binding activity, demonstrating that the impaired IL-18-induced NF- κ B activity in MyD88-deficient cells was not due to the abnormal function or impairment of regulating ability of NF- κ B.

[0061] In addition to induction of NF- κ B activation, IL-1 is also known to activate c-Jun N-terminal kinase (JNK). To test whether IL-18 induces JNK activation, an in vitro kinase assay was carried out using GST-c-Jun-fusion protein as a substitute. Treatment with IL-18 induced JNK activation in Th1-developing cells of wild-type mice. However, IL-18-induced JNK activation was not observed in MyD88-deficient cells. By contrast, normal activation of JNK was observed in MyD88-deficient cells treated with TNF- α . IL-18-induced NF- κ B and JNK activation was impaired in MyD88-deficient mice. These results demonstrate that MyD88 is essential for IL-18-induced activation of both NF- κ B and JNK.

Example 5 (Unresponsiveness of macrophages and splenic B cells of MyD88 knockout mice to bacterial cell wall components)

5-1 (Generation of TLR4-deficient mice)

[0062] It has recently been reported that C3H/HeJ mice are hyporesponsive to LPS because of a missense point mutation in the Toll-like receptor (TLR)-4 gene (Science 282, 2085-8, 1998, J. Exp. Med. 189, 615-625, 1999, J. Immunol. 162, 3749-3752, 1999), and the inventors have demonstrated that macrophages and splenic B cells of TLR4-deficient mice are hyporesponsive to LPS, and that TLR4 gene is essential for LPS signaling (J. Immunol. 162, 3749-3752, 1999). In order to compare the responsiveness of macrophages and splenic B cells of TLR4- and MyD88-deficient mice to bacterial cell wall components, TLR4-deficient mice (F₂ interbred from 129/01aXC57BL/6) were generated by gene targeting as described previously (J. Immunol. 162, 3749-3752, 1999). Age-matched groups of wild-type, TLR4-, and MyD88-deficient mice were used for the following examples.

5-2 (Preparation of bacterial cell wall components)

[0063] LPS of *Escherichia coli* Serotype 055:B5 (Sigma), *Klebsiella pneumoniae* (Sigma), *Pseudomonas aeruginosa* Serotype 10 (Sigma), *Salmonella typhimurium* (Sigma), *Serratia marcescens* (Sigma), *Shigella flexneri* Serotype 1A (Sigma) and *Vibrio cholerae* Serotype Inaba 569B (Sigma) and the like were purchased. They were prepared by phenol extraction and purified by gel filtration. LPS from *Salmonella minnesota* Re-595 prepared by phenol-chloroform-petroleum ether extraction procedure was also purchased (Sigma). LPS and Lipid A of *Porphyromonas gingivalis* 381 was prepared by the method as described previously (FEBS Lett. 332, 1994, 197-201). Whole cell lysates of *Mycobacterium tuberculosis* was prepared by the following process: *Mycobacterium tuberculosis* Aoyama B strain (NIHJ 1635) was cultured in Dubos broth (DIFCO) for 1 month; cells were collected and resuspended with phosphate buffered saline (PBS); cells were sonicated.

5-3 (Preparation of peritoneal macrophages)

[0064] 2 ml of 4% thioglycollate was intraperitoneally injected into the generated wild-type, TLR4- and MyD88-deficient mice respectively. Three days later, peritoneal exudate cells were isolated from the peritoneal cavity and washed with ice-cold Hank's buffered salt solution (HBSS), then peritoneal cells were obtained. The cells were made to float in

RPMI1640 medium, then put in plastic plates separately, and cultured for 2 hours at 37°C and washed with Hank's buffered salt solution to remove nonadherent cells. Adherent cells were used as peritoneal macrophages in the experiments below.

5 5-4 (Unresponsiveness to LPS of Salmonella minnesota Re-595)

[0065] Responsiveness of each peritoneal macrophage of the wild-type (wild-type), TLR4-deficient (TLR4^{-/-}), MyD88-deficient (MyD88^{-/-}) mice and the like to LPS were examined with LPS of Salmonella minnesota Re-595. Peritoneal macrophages from each mouse were cultured for 24 hours in the presence of various concentrations (0, 0.01, 0.1, 1, 10 or 100 μg/ml) of LPS and stimulated, then concentration of tumor necrosis factor (TNF-α) released from LPS-responsive macrophages was measured by ELISA (see Fig. 8A). By these results, it has been found that production of TNF-α increases in response to LPS in a dose-dependent manner in macrophages of wild-type mice, by contrast, no production of TNF-α is observed in TLR4- or MyD88-deficient mice even when they receive LPS stimuli at a concentration of 100 μg/ml, and that these mice are LPS-unresponsive.

10
15 [0066] Further, responsiveness of splenic B cells to LPS of Salmonella minnesota Re-595 was examined. Splenic B cells (1×10^5) of each of the wild-type, TLR4- and MyD88-deficient mice were isolated, cultured in 96-well plates and stimulated by various concentrations (0, 0.01, 0.1, 1, 10 or 100 μg/ml) of LPS. 1 μCi of [³H]-thymidine (DuPont) was added 40 hours after onset of the culture, then the cells were cultured for another 8 hours, and [³H] uptake was measured by a β scintillation counter (Packard) (see Fig. 8B). As a result, LPS-induced proliferative response was promoted in response to LPS in a dose-dependent manner in splenic B cells of wild-type mice, by contrast, no LPS-induced proliferative response was observed in splenic B cells of both TLR4- and MyD88-deficient mice.

20
25 [0067] The expression of major histocompatibility complex (MHC) class II (I-A^b molecule) on the surface of splenic B cells in response to Re-595 LPS was examined by flow cytometry. Splenic B cells (1×10^6) from each of the wild-type, MyD88- and TLR4-deficient mice were cultured for 48 hours in the presence of various concentrations (0, 0.01, 0.1, 1, 10 or 100 μg/ml) of LPS. After the culture, the cells were collected and then stained by combining I-A^b molecule on the surface of the cells and FITC-labelled antibody which is constructed by combining phycoerythrin (PE; PharMingen)-conjugated anti-B220 antibody or biotinylated anti-mouse I-A^b antibody (PharMingen) and fluorescein isocyanate (FITC; PharMingen)-conjugated streptavidin. The stained cells were analyzed on fluorescence-activated cell sorter Calibur (FACS Calibur) using CELLQuest software (Becton Dickinson). As a result, Re-595 LPS caused an increase in the expression of I-A^b molecule on the surface of splenic B cells of wild-type mice. In contrast, Re-595 LPS did not enhance I-A^b molecule expression in splenic B cells of either TLR4- or MyD88-deficient mice, even when stimulated with high concentration of LPS (100 μg/ml)(see Fig. 8C). The above-mentioned results indicate that both TLR4- and MyD88-deficient mice are unresponsive to LPS of Salmonella minnesota Re-595.

35 5-5 (Responsiveness of TLR4- and MyD88-deficient mice to IL-4 and IFN-γ)

[0068] In order to examine whether splenic B cells of TLR4- and MyD88-deficient mice are unresponsive to all stimuli, the responsiveness of splenic B cells of TLR4- and MyD88-deficient mice to other stimuli were investigated. The investigation demonstrates that there was no impairment as to their responsiveness to the stimuli as described below, and that these mice were specifically defective in their response to LPS.

40
45 [0069] Splenic B cells (1×10^5) from each of the wild-type, MyD88- and TLR4-deficient mice were isolated, cultured for 40 hours in the presence of both IL-4 (Genzyme) and anti-IgM antibody, or in the presence of anti-CD40 antibody, then [³H]-thymidine (DuPont) was added and the cells were cultured for another 8 hours, and [³H] uptake was measured by a β scintillation counter (see Fig. 9A). As a result, splenic B cells of both TLR4- and MyD88-deficient mice showed same reaction as splenic B cells of wild-type mice with regard to the response to IL-4 and the mixture of anti-IgM antibody, or to the anti-CD40 antibody.

[0070] Next, Splenic B cells (1×10^6) from each of the wild-type, MyD88- and TLR4-deficient mice were cultured for 48 hours in the presence or absence of 100 U/ml of IL-4, and then stimulated. Subsequently, the cells were stained by combining I-A^b molecule on the surface of the splenic B cells and PE-conjugated anti-B220 antibody or FITC-conjugated anti-mouse I-A^b antibody. The cell proliferation was measured on fluorescence-activated cell sorter Calibur using CELLQuest software (see Fig. 9B). As a result, splenic B cells of both TLR4- and MyD88-deficient mice showed same reaction as those of wild-type mice with regard to the response to IL-4 as well.

50
55 [0071] Each of wild-type, MyD88- and TLR4-deficient mice were intraperitoneally injected with 5000 U of IFN-γ (Genzyme) or PBS. Three days after injection, peritoneal macrophages were collected and stained by combining I-A^b molecule on the surface of the macrophage membranes and FITC-conjugated anti-mouse I-A^b antibody, then analyzed by fluorescence-activated cell sorter Calibur using CELLQuest software (see Fig. 9C). The result indicated that the expression of I-A^b molecule in peritoneal macrophages, in other words, blockage level of IFN-induced cell proliferation was comparative among wild-type, MyD88- and TLR4-deficient mice.

5-6 (Analysis of phagocytosis)

[0072] Macrophages of wild-type, MyD88- and TLR4-deficient mice added with 0.025 % of fluorescent latex beads (0.75 μm) (Polyscience) were cultured for 2 hours at 37°C in a CO₂ incubator. Then the culture materials were washed vigorously three times with PBS to remove non-phagocytosed beads and incubated with PBS containing 2.5 % of formaldehyde for 20 minutes, and fixed with formaldehyde. Visualization of these fixed cells with Axiophoto microscope (Carl Zeiss, Inc.) showed that peritoneal macrophages of both TLR4- and MyD88-deficient mice phagocytosed the latex particles, and therefore, that phagocytic ability of the macrophages of TLR4- and MyD88-deficient mice were not impaired by these other stimuli.

5-7 (Responsiveness to LPS of *Porphyromonas gingivalis*)

[0073] As LPS of *Porphyromonas gingivalis* shows some reaction in its ability to activate cells of LPS-hyporesponsive C3H/HeJ mice (J. Immunol. 158, 1997, 4430-6), responsiveness of each mouse to LPS of *Porphyromonas gingivalis* was examined as in the case with *Salmonella minnesota* Re-595. In macrophages of wild-type mice, TNF- α was induced in response to LPS of *Porphyromonas gingivalis* in a dose-dependent manner. However, macrophages of TLR4-deficient mice were hyporesponsive like those of C3H/HeJ mice, and only showed the TNF- α producibility which was about one third of that of wild-type mice macrophages. In contrast, macrophages of MyD88-deficient mice did not produce any detectable TNF- α , even when stimulated with high concentration of LPS (see Fig. 10A).

[0074] Splenic B cells of TLR4-deficient mice exhibited low level proliferative response to LPS of *Porphyromonas gingivalis* 381, and enhanced the expression of I-A^b molecule of splenic B cells, however, splenic B cells of MyD88-deficient mice did not exhibit proliferative response and the expression of I-A^b molecule could not confirmed (see Fig. 10B and C). Further, the same results were obtained with lipid A of *Porphyromonas gingivalis* 381. This indicates that TLR4-deficient mice are hyporesponsive and MyD88-deficient mice are unresponsive to LPS of *Porphyromonas gingivalis*. In addition, it has been found that MyD88 is essential for the signaling induced by LPS of *Porphyromonas gingivalis*, whereas TLR4 shows partial contribution.

5-8 (Responsiveness to LPS of *Escherichia coli* 055:B5)

[0075] Responsiveness to LPS of *Escherichia coli* 055:B5 was examined as in the case with *Salmonella minnesota* Re-595. The responsiveness to LPS of *Escherichia coli* (055:B5) was impaired in peritoneal macrophages of both TLR4- and MyD88-deficient mice, compared with those of wild-type mice (Fig. 11A). However, when stimulated with high concentration of LPS, macrophages of TLR4-deficient mice produced a small amount of TNF- α . In contrast, macrophages of MyD88-deficient mice did not produce TNF- α even when stimulated with high concentration of LPS.

[0076] Similar tendencies were observed in proliferative responses in splenic B cells of these mice (see Fig. 11B). Furthermore, when stimulated with LPS at a concentration over 10 $\mu\text{g/ml}$, splenic B cells of TLR4-deficient mice showed a certain expression level of I-A^b molecule similar to the level shown by splenic B cells of wild-type mice. In contrast, splenic B cells of MyD88-deficient mice did not show I-A^b molecule expression even when stimulated with LPS at a concentration of 100 $\mu\text{g/ml}$ (see Fig. 11C). As in the case of stimuli with LPS of *Porphyromonas gingivalis*, these results indicate that TLR4-deficient mice are hyporesponsive and MyD88-deficient mice are unresponsive to LPS of *Escherichia coli* (055:B5).

5-9 (Responsiveness to peptidoglycan)

[0077] It has been reported that Peptidoglycan (PGN), which is a major cell wall component of Gram-positive bacteria, activates macrophages (J. Immunol. 155, 1995, 2620-30, Infect. Immun. 62, 1994, 2715-21). Therefore, responsiveness to PGN of *Staphylococcus aureus* (Fluka) was examined as in the case with *Salmonella minnesota* Re-595. When stimulated with PGN, peritoneal macrophages of TLR4-deficient mice produced TNF- α in a dose-dependent manner to almost the same extent as macrophages of wild-type mice. In contrast, macrophages of MyD88-deficient mice did not produce TNF- α even when stimulated with high concentration of PGN (see Fig. 12A).

[0078] When stimulated with PGN of *Staphylococcus aureus*, splenic B cells of wild-type mice displayed proliferative responses, and the proliferative response was severely impaired in peritoneal macrophages of MyD88-deficient mice compared with those of wild-type mice, but in TLR4-deficient mice, the proliferative response was not severely impaired as in MyD88-deficient mice (see Fig. 12B). Further, when stimulated with PGN at a concentration over 10 $\mu\text{g/ml}$, splenic B cells of TLR4-deficient and wild-type mice showed enhancement of I-A^b molecule expression. In contrast, splenic B cells of MyD88-deficient mice did not show enhancement of I-A^b molecule expression even when stimulated with PGN at a concentration of 100 $\mu\text{g/ml}$ (see Fig. 12C). Thus, TLR4-deficient mice showed almost the same response to PGN of *Staphylococcus aureus* as wild-type mice, while MyD88-deficient mice showed no responsiveness.

5-10 (Responsiveness to lipoteichoic acid)

[0079] As lipoteichoic acid (LTA) is a cell wall component of Gram-positive bacteria and induces activation of monocytes and macrophages (Infect. Immun. 62, 1994, 2715-21), responsiveness to LTA of *Streptococcus pneumoniae* was examined as in the case with *Salmonella minnesota* Re-595. Peritoneal macrophages of wild-type mice increased production of TNF- α in response to LTA in a dose-dependent manner. In contrast, macrophages of MyD88-deficient mice did not produce TNF- α even when stimulated with high concentration of LTA. In comparison with peritoneal macrophages of wild-type mice, TNF- α production was also impaired in those of TLR4-deficient mice, however, TNF- α was induced when stimulated with 100 μ g/ml of LTA (see Fig. 13A).

[0080] Next, proliferative responses and enhancement of I-A^b molecule expression in splenic B cells of these mice in response to stimulation from LTA of *Streptococcus pneumoniae* was analyzed (see Fig. 13B). The results indicated that splenic B cells of wild-type mice enhanced their response to LTA in a dose-dependent manner, whereas splenic B cells of MyD88-deficient mice exhibited a severely defective proliferative response to LTA. Though splenic B cells of TLR4-deficient mice also exhibited an impaired proliferative response, they exhibited proliferative response when stimulated with high concentration of LTA. Further, in splenic B cells of wild-type and TLR4-deficient mice, enhancement of I-A^b molecule expression was also observed on the cell surface, whereas no enhancement was observed in those of MyD88-deficient mice (see Fig. 13C). This indicates that MyD88-deficient mice are unresponsive to stimulation from LTA of *Streptococcus pneumoniae*.

5-11 (Responsiveness to whole cell lysates of Mycobacterial tuberculosis)

[0081] As cell wall components of Mycobacterial tuberculosis, especially lipoarabinomannan, are known to induce activation of myeloid cells (J. Immunol. 149, 1992, 541-7, J. Clin. Invest. 91, 1993, 2076-83), responsiveness to whole cell lysates of Mycobacterial tuberculosis was examined as in the case with *Salmonella minnesota* Re-595. Macrophages of wild-type mice produced TNF- α in response to the whole lysates in a dose-dependent manner. Macrophages of TLR4-deficient mice also exhibited TNF- α production though the production amount was smaller than those of wild-type mice. However, macrophages of MyD88-deficient mice did not produce TNF- α in response to the whole cell lysates of Mycobacterial tuberculosis at a high concentration (see Fig. 14A).

[0082] Next, responsiveness of these mice to stimulation from whole cell lysates of Mycobacterial tuberculosis was examined. Splenic B cells of wild-type mice exhibited enhancement of proliferative responses and I-A^b molecule expression on the surface of the cells in response to the whole cell lysates in a dose-dependent manner. Splenic B cells of TLR4-deficient mice also showed proliferative responses and I-A^b molecule expression, although these responses were lower than those of splenic B cells of wild-type mice. In contrast, splenic B cells of MyD88-deficient mice displayed severely impaired proliferative responses and enhancement of I-A^b molecule expression, indicating that they are unresponsive to the whole cell lysates (see Fig. 14B and C).

5-12 (Responsiveness to other bacterial cell wall components)

[0083] Responsiveness of wild-type, TLR4- and MyD88-deficient mice to other bacterial cell wall components [LPSs of *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* 10, *Salmonella typhimurium*, *Shigella flexneri*, *Vibrio cholerae* and the like, and PGN of *Staphylococcus epidermidis*, which is provided from Shigeo Kawata of Daiippon Pharmaceutical Co.] was examined in a same manner as aforementioned. The results are shown in Table 1. This Table 1 shows that MyD88-deficient mice are unresponsive to all bacterial cell components.

Table 1

Sample	Responsiveness of mice		
	wild-type	TLR4-/-	MyD88-/-
LPS			
<i>Escherichia coli</i> 055:B5	++	+	-
<i>Klebsiella pneumoniae</i>	++	-	-
<i>Porphyromonas gingivalis</i>	++	+	-
<i>Pseudomonas aeruginosa</i>	++	+	-
<i>Salmonella minnesota</i> Re595	++	-	-
<i>Salmonella typhimurium</i>	++	+	-
<i>Serratia marcescens</i>	++	+	-
<i>Shigella flexneri</i>	++	+	-
<i>Vibrio cholerae</i>	++	+	-

EP 1 716 752 B1

(continued)

	Sample	Responsiveness of mice		
LPS		wild-type	TLR4 ^{-/-}	MyD88 ^{-/-}
<hr/>				
5	PGN	<hr/>		
	Staphylococcus aureus	++	++	-
	Staphylococcus epidermidis	++	+	-
<hr/>				
10	LTA	<hr/>		
	Streptococcus faecalis	++	+	-
<hr/>				
	whole cell lysates of Mycobacterium tuberculosis	<hr/>		
	Mycobacterium tuberculosis	++	+	-
<hr/>				

15
20
25
30
35
40
45

[0084] It has been found that LPS can be classified into two types: one type includes LPSs which utilize TLR4 as their unique signaling receptor and show unresponsiveness (LPSs of Salmonella minnesota Re595, Klebsiella pneumoniae and the like); another type includes LPSs which show hyporesponsiveness to TLR4-deficient mice (LPSs of Porphyromonas gingivalis, Escherichia coli 055:B5, Pseudomonas aeruginosa, Shigella flexneri, Salmonella typhimurium, Vibrio cholerae and the like). Since MyD88-deficient mice show no responsiveness to these latter LPSs, it is presumed that the recognition and signaling of these LPSs are mediated by both TLR4 and other TLRs, and/or by TLR-related receptors that use MyD88 as an adaptor molecule.

Example 6 (Generation of TLR2 knockout mice - for reference only)

25
30
35

[0085] TLR2 gene was screened from 129/SvJ mouse genomic library (Stratagene) using a probe derived from a mouse EST clone (accession number D77677) similar to human TLR2 gene, and subcloned into pBluescript vector (Stratagene), then characterized by restriction enzyme mapping and DNA sequencing. A targeting vector was constructed by replacing a gene fragment at an exon region 1.3 kb containing cytoplasmic domain of TLR2 gene with pMC1-neo (Stratagene) having Poly A signal. The targeting vector was flanked by a 4.8 kb 5' genomic fragment and a 1.0 kb 3' fragment and contained an HSV-tk cassette at the 5' terminal. The targeting vector was linearized with Sall and electroporated into E14.1 embryonic stem cells (ES cells). 120 clones resistant to G418 and gancyclovir were screened for homologous recombination by PCR and 9 clones were confirmed by Southern blot analysis using the probe indicated in Figure 15A.

35
40
45

[0086] Chimeric mice were generated by microinjection of 3 targeted ES clones containing a homologously recombined mutant TLR2 allele into blastocysts of C57BL/6 mice. Male chimeric mice were bred to C57BL/6 females to produce heterozygous mice. The heterozygous mice were intercrossed to obtain homozygotes (Fig 15B). TLR2-deficient mice could be generated at the expected Mendelian ratio, and did not show any obvious abnormality until 20 weeks.

[0087] To confirm that the homologous recombination caused inactivation of the TLR2 gene, total RNA (15 pg) was extracted from peritoneal macrophages (5×10^6) of wild-type (+/+) and TLR2 knockout (-/-) mice and then electrophoresed, transferred to a nylon membrane, and Northern blot analysis was conducted using cDNA specific to [³²P]-labelled TLR2, or cDNA specific to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as the method previously described (Immunity 9, 143-150, 1998). As a result, TLR2 mRNA was not detected in peritoneal macrophages of TLR2-deficient mice (Fig 15C). In addition, it was shown that the expressions of CD3, B220, CD4, and CD8 in thymocytes and splenocytes of TLR2 knockout mice were not different from those of wild-type mice (data not shown).

Example 7 (Responsiveness of TLR2 knockout mice to endotoxin - for reference only)

50
55

[0088] 1 mg of LPS derived from Escherichia coli (055:B5) was injected into each of TLR2 knockout mice (n=5), TLR4 knockout mice (n=5) and wild-type mice (n=5), and LPS unresponsiveness was examined by their survival rate. The results are shown in Fig. 16. Fig. 16 confirms that though TLR2 knockout mice (TLR2^{-/-}) and wild-type mice responded to LPS and almost all of them died within 4 days after injection, none of TLR4 knockout mice (TLR4^{-/-}) died even after 6 days after injection, and that TLR4 knockout mice are unresponsive to endotoxin.

Example 8 (Responsiveness of TLR2 knockout mice to cell components of Gram-negative bacteria - for reference only)

[0089] Each of TLR2 knockout (TLR2^{-/-}), TLR4 knockout (TLR4^{-/-}) and wild-type (wild-type) mice were intraperitoneally injected with 2 ml of 4% thioglycollate medium (DIFCO). Three days later, peritoneal exudate cells were isolated from

the peritoneal cavity of each mouse. These cells were cultured in RPMI1640 medium (GIBCO) supplemented with 10% fetal bovine serum (GIBCO) for 2 hours at 37°C and washed with ice-cold Hank's buffered salt solution (HBSS; GIBCO) to remove nonadherent cells. Adherent cells were used as peritoneal macrophages for following experiments.

[0090] Each of obtained peritoneal macrophages were cultured for 24 hours with 1.0 ng/ml of synthetic lipid A derived from *Escherichia coli* (compound 506; Daiichi Pure Chemicals) or LPS derived from *Salmonella minnesota* Re-595 (Sigma) in the presence or absence of IFN- γ (30 unit/ml). Synthetic lipid A, which was soluble in endotoxin-free water and containing 0.025% of triethylamine, was used as said synthetic lipid A. After the culture, production amounts of IL-6 (Fig. 17A), TNF- α (Fig. 17B) and NO₂⁻ (Fig. 17C) in culture supernatants were measured. Production amount of IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; ENDOGEN), and that of TNF- α was measured by ELSIA, according to manufacturer(Genzyme)'s instructions, and that of NO₂⁻ was measured by the Greiss method using NO₂/NO₃ Assay Kit (Dojindo Laboratories).

[0091] These results indicate that macrophages of wild-type mice and TLR2 knockout mice showed similar responsiveness to LPS and lipid A, and produced IL-6 and TNF- α , and it was confirmed that production of TNF- would be further increased when IFN- γ was added to LPS or lipid A before the culture. By contrast, macrophages of TLR4 knockout mice produced neither IL-6 nor TNF- α . Further, production of NO₂⁻ was confirmed by culturing macrophages of wild-type and TLR2 knockout mice with IFN- γ -added lipid A or LPS. The obtained results were same as those aforementioned even in the case the injection amount of lipid A or LPS was arranged to be 1 μ g/ml (data not shown).

[0092] Next, each of peritoneal macrophages of wild-type, TLR2 knockout and TLR4 knockout mice were cultured in the presence of LPS derived from *Salmonella minnesota* Re-595 at various concentrations shown in Fig. 17D, and production of TNF- α was measured. The results indicate that macrophages of wild-type mice and TLR2 knockout mice showed similar tendency to increase in response to LPS in a dose-dependent manner, while macrophages of TLR4 knockout mice produced no TNF- α in response to any concentration of LPS.

Example 9 (Responsiveness to LPS of *Salmonella minnesota* Re-595 - for reference only)

[0093] Responsiveness of splenocytes of various mice (wild-type, TLR2^{-/-} and TLR4^{-/-}) to LPS of *Salmonella minnesota* Re-595 were examined. Splenocytes (1×10^5) of each mouse were isolated and then cultured and stimulated in 96-well plates with various concentrations of LPS shown in Fig. 18A. 1 μ Ci of [³H]-thymidine (DuPont) was added 40 hours after the onset of the culture, and cells were further cultured for 8 hours, then [³H] uptake was measured by a β scintillation counter (Packard) (Fig. 18A). As a result, the cell proliferative response was promoted in response to LPS in a dose-dependent manner in splenocytes of wild-type and TLR2 knockout mice as well. By contrast, whatever the concentration of LPS as a stimulus would be, no LPS-induced cell proliferative response was observed in splenocytes of TLR4-deficient mice.

[0094] In addition, the expression of major histocompatibility complex (MHC) class II (I-A^b) on the surface of B cells in response to Re-595 LPS was examined by flow cytometry. Splenic B cells (1×10^5) of each of wild-type, TLR2 knockout (2^{-/-}) and TLR4 knockout (4^{-/-}) mice were isolated and cultured for 48 hours in 96-well plates with various concentrations (0, 10¹, 10², 10³, 10⁴ or 10⁵ ng/ml) of LPS or 100 U/ml of IL-4. After the culture, the cells were collected and stained by combining I-A^b molecule on the surface of the cells and FITC-labelled antibody which is constructed by combining phycoerythrin (PE; PharMingen)-conjugated anti-B220 antibody or biotinylated anti-mouse I-A^b antibody (PharMingen) and fluorescein isocyanate (FITC; PharMingen)-conjugated streptavidin. The stained cells were analyzed on fluorescence-activated cell sorter Calibur (FACS Calibur) using CELLQuest software (Becton Dickinson) (Fig. 18B). As a result, Re-595 LPS enhanced the expression of I-A^b molecule on the surface of splenic B cells of wild-type and TLR2 knockout mice. In contrast, I-A^b molecule expression in splenic B cells of TLR4-deficient mice were not enhanced by Re-595 LPS, even when stimulated with high concentration of LPS (10⁵ ng/ml). The above-mentioned results indicate that TLR2 knockout mice show responsiveness to LPS as wild-type mice did. When stimulated with IL-4, each knockout mice show normal expression of I-A^b molecule on the surface of splenic B cells.

Example 10 (Unresponsiveness of macrophages of TLR2 knockout mice to cell wall components derived from Gram-positive bacteria - for reference only)

[0095] Responsiveness of each peritoneal macrophages of said wild-type (wild-type), TLR2 knockout (TLR2^{-/-}), TLR4 knockout (TLR4^{-/-}) mice and the like to cell wall components derived from Gram-positive bacteria were examined with prepared cell wall specimens of *S. aureus*, *C. diphtheriae* and *N. coeliaca*. The cell specimens were prepared in accordance with the method previously described (Biken J. 18, 77-92, 1975, Infect. Immun. 38, 817-824, 1982), that is, bacterial cells grown under appropriate cultural conditions were disrupted with either a Braun mechanical cell homogenizer (model MSK; B. Braun Apparatebau) or a Dyno-Mill (type KDL; Willy A, Biochofen Manufacturing Engineers). A crude cell wall fraction obtained by differential centrifugation of a disrupted cell suspension was purified and prepared by removal of components noninherent in cell walls with protease treatment.

[0096] Peritoneal macrophages of each mouse were cultured for 24 hours in the presence of various concentrations (0, 0.1, 1, 10 or 100 $\mu\text{g/ml}$) of said preparations and stimulated, then concentration of tumor necrosis factor (TNF- α) released from each macrophage was measured by ELISA (Fig. 19). By these results, it has been found that production of TNF- in response to cell wall components derived from Gram-positive bacteria was more impaired in macrophages of TLR2 knockout mice than in those of wild-type and TLR4 knockout mice.

Example 11 (Responsiveness of TLR2 knockout mice to cell wall components of Gram-positive bacteria - for reference only)

[0097] Next, it was investigated that which cell wall component of Gram-positive bacteria activated macrophages via TLR2. As it has been reported that both peptidoglycan, which is a cell wall component of Gram-positive bacteria, and lipoteichoic acid (LTA) activate monocytes / macrophages (Infect. Immun. 60, 3664-3672, 1992, Immunity 1, 509-516, 1994, J. Biol. Chem. 271, 23310-23316, 1996, Infect. Immun. 64, 1906-1912, 1996), production amounts of IL-6 and NO_2^- in response to peritoneal macrophages of various kinds of mouse were measured in accordance with the same method as in example 8, with 10 $\mu\text{g/ml}$ of Staphylococcus aureus PGN (Fluka; Fig. 20A) or 10 $\mu\text{g/ml}$ of Staphylococcus aureus LTA (Sigma; Fig. 20C). Further, production of TNF- α in peritoneal macrophages of various kinds of mouse in response to PGN (Fig. 20B) or LTA (Fig. 20D) were measured in accordance with the same method as in example 10.

[0098] The results shown in Fig. 20A indicates that: peritoneal macrophages of wild-type and TLR4 knockout mice produced IL-6 in response to PGN, in contrast, those of TLR2 knockout mice produced no IL-6; NO_2^- was produced when peritoneal macrophages of wild-type and TLR4 knockout mice were cultured with PGN in the presence of IFN- γ , in contrast, no NO_2^- was produced when those of TLR2 knockout mice were used; IL-6 was produced in peritoneal macrophages of wild-type and TLR2 knockout mice in response to LTA, in contrast, no IL-6 was produced in those of TLR4 knockout mice (Fig. 20C); NO_2^- was produced when peritoneal macrophages of wild-type and TLR2 knockout mice were cultured with LTA in the presence of IFN- γ , in contrast, no NO_2^- was produced when those of TLR4 knockout mice were used (Fig. 20C).

[0099] As shown in Fig. 20B, peritoneal macrophages of TLR4 knockout mice, as well as those of wild-type mice, increased production of TNF- α in response to PGN in a dose-dependent manner, in contrast, those of TLR2 knockout mice showed substantial impairment in production of TNF- α , indicating that TLR2 knockout mice were unresponsive to PGN. As shown in Fig. 20D, peritoneal macrophages of TLR2 knockout mice, as well as those of wild-type mice, induced production of TNF- α in response to LTA in a dose-dependent manner, in contrast, no TNF- α was produced in those of TLR4 knockout mice, indicating that TLR4 knockout mice were unresponsive to LTA. These results demonstrate that PGN, which is a cell wall component of Gram-positive bacteria, activates macrophages via TLR2, and that LTA activates macrophages via TLR4.

Example 12 (LPS or PGN-stimulated in vitro kinase assay and Western blot analysis - for reference only)

[0100] TLR family members are known as intracellular signaling molecules which activate a serine-threonine kinase IRAK via an adapter protein MyD88, and subsequently activate rel-type transcription factor, NF- κB (Mol. Cell 2, 253-258, 1998, J. Exp. Med. 187, 2097-2101, 1998, Immunity 11, 115-122, 1999). Whether LPS and PGN activate the intracellular signaling molecules was examined as follows: peritoneal macrophages (1×10^6) of various kinds of mouse were stimulated with 1 ng/ml of LPS of Salmonella minnesota Re-595 or 1 $\mu\text{g/ml}$ of PGN of Staphylococcus aureus for the period indicated in Fig. 21; these bacterial cell components were lysed in lysis buffer (buffer containing Triton X-100 at a final concentration of 1.0 %, 137 mM of NaCl, 20 mM of Tris-HCl, 5 mM of EDTA, 10 % of glycerol, 1 mM of PMSF, 20 $\mu\text{g/ml}$ of Aprotinin, 20 $\mu\text{g/ml}$ of Leupeptin, 1 mM of Na_3VO_4 , and 10 mM of β -glycerophosphate; pH 8.0): the cells were immunoprecipitated with anti-IRAK antibody (Hayashibara Biochemical Laboratories, Inc.); in vitro kinase assay were conducted as previously described (Biochem. Biophys. Res. Commun. 234, 183-196, 1998, Immunity 11, 115-122, 1999); autophosphorylation of IRAK were measured (Auto shown in Fig. 21A and B).

[0101] The lysates were dissolved by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blotted with anti-IRAK antibody (Transduction Laboratories) and visualized by using the enhanced chemiluminescence system (DuPont) (WB in Fig. 21A and B). These results show that IRAK activation in response to LPS was observed in wild-type (wild-type) and TLR2 knockout (TLR2-/-) mice, but not observed in TLR4 knockout (TLR4-/-) mice. In contrast, IRAK activation in response to PGN was observed only in wild-type and TLR4 knockout mice. Thus indicates that LPS is recognized via TLR4, and that PGN is recognized via TLR2 respectively.

[0102] NF- κB activation in response to LPS or PGN was also investigated. Macrophages of various kinds of mouse were stimulated with said LPS or PGN, then nuclear extracts from the macrophages were purified and incubated with a probe specific to DNA binding site of NF- κB , and visualized by electrophoretic mobility shift assay as described previously (Immunity 9, 143-150, 1998). The results are shown in Fig. 21C and D. Arrows in Fig. 21C and D indicate the position of a complex comprised of NF- κB and the specific probe, and arrowheads indicate the position of specific

EP 1 716 752 B1

probe only. As a result, DNA binding activity of NF- κ B in response to LPS was detected in nuclear extracts from macrophages of wild-type and TLR2 knockout mice, but not in those of TLR4 knockout mice. In contrast, NF- κ B activation in response to PGN was observed in macrophages of wild-type and TLR4 knockout mice but not in those of TLR2 knockout mice. Thus indicates that TLR4 is essential for LPS-induced NF- κ B activation, and that TLR2 is essential for PGN-induced NF- κ B activation.

Example 13 (Stereospecific lipopeptide synthesis and HPLC purification of R- and S-MALP-2)

[0103] The stereoisomers of S-(2,3-dihydroxypropyl)-L-cystein were synthesized as described previously (Int. J. Peptide Protein. Res. 38, 545, 1991) using two reagents, (S)-(-)-glycidol and (R)-(+)-glycidol (Sigma-Aldrich), which contain enantiomers purified to 99 % or over respectively, as starting materials. The isomers of N-fluorenylmethoxycarbonyl-protected S-[2(S), 3-bis(palmitoyloxy)propyl]-L-cystein and S-[2(R), 3-bis(palmitoyloxy) propyl]-L-cystein were synthesized respectively from these stereoisomers and coupled according to the previously described method, and a carrier-bound fluorenylmethoxycarbonyl-protected peptide was obtained. 10 mg of crude MALP-2 was further purified in batch treatment by reversed phase HPLC using SP 250/10 Nucleosil 300-7 C8 column (Macherey & Nagel) and was eluted at 40°C with a linear gradient of water/2-propanol containing 0.1% trifluoroacetic acid. Elution of active material was monitored by the NO release assay. The final product was characterized by mass spectroscopy and amino acid analysis for determination of the exact peptide content. MALP-2 was prepared to be a concentration of 1 mg/ml using a solution of water/2-propanol 1:1 (v/v) and stored at 4°C.

Example 14 (Responsiveness of peritoneal macrophages of CH3/HeJ mice to lipoprotein/lipopeptide)

[0104] PEC (peritoneal exudate cells) were isolated from endotoxin-hyporesponsive mice derived from CH3/HeJ, and these PEC (6×10^5) were cultured overnight at 37°C in 24-well cell culture plates having 1.25 ml of Dulbecco MEM medium (DMEM) which contained 5 % of FCS and 25 μ M of 2-mercaptoethanol. Peritoneal macrophages were prepared by removing nonadherent cells from the cultured material and exchanging the culture liquid for fresh one. The peritoneal macrophages were cultured in the presence of both various concentrations (0.1, 1, 10, 10^2 , 10^3 , 10^4 , 10^5 or 10^6 pg/ml) of R-MALP-2 or S-MALP-2 obtained by the method described in example 13 and recombinant interferon- γ (rIFN- γ) at a concentration of 30 unit/ml, and production amounts of NO $_2^-$, TNF- α and IL-6 in the culture supernatants were measured (Fig. 22). TNF- α was measured by ELISA (Genzyme) at 3 hours after the onset of the culture, IL-6 was measured by ELISA (ENDOGEN) at 21 hours after the onset of the culture, and NO $_2^-$ was measured by Greiss method using NO $_2$ /NO $_3$ assay kit (Dojindo Laboratories) at 46 hours after the onset of the culture. These results indicate that R-MALP-2 shows higher specific activity to peritoneal macrophages than S-MALP-2.

Example 15 (Responsiveness of human monocytes to a lipoprotein/lipopeptide)

[0105] Human monocytes from healthy volunteers were washed and used for experiments. With various concentrations (0.1, 1, 10, 10^2 , 10^3 , 10^4 or 10^5 pg/ml) of R-MALP-2 or S-MALP-2 obtained by the method in example 13, human monocytes (7.5×10^5) were stimulated for 20 hours. After stimulation, production amounts of IL-8, MCP-1 and TNF- α were measured by ELISA (Fig. 23). The results indicate that R-MALP-2 shows higher specific activity to human monocytes which have not yet differentiated to macrophages or the like than S-MALP-2 as shown in macrophages derived from the mice in example 14.

Example 16 (Unresponsiveness of TLR2 knockout mice to a lipoprotein/lipopeptide)

[0106] Responsiveness of each peritoneal macrophage of wild-type (wild-type), TLR2 knockout (TLR2 $^{-/-}$), TLR4 knockout (TLR4 $^{-/-}$), and MyD88 knockout (MyD88 $^{-/-}$) mice to a lipoprotein/lipopeptide was examined with MALP-2 derived from mycoplasma. Peritoneal macrophages of each mouse were isolated by the method described in example 14, and each of peritoneal macrophages were cultured for 24 hours with various concentrations (0, 0.1, 1, 10, 10^2 , 10^3 , or 10^4 pg/ml) of R-MALP-2 or S-MALP-2 obtained in example 13, in the presence (Fig. 24B and D) or absence (Fig. 24 A and C) of rINF γ (30 unit/ml). After the culture, production amounts of TNF- α and NO $_2^-$ in the culture supernatants were measured (Fig. 24).

[0107] The results indicate that production of TNF- α and NO $_2^-$ increased in response to R-MALP-2 in a dose-dependent manner in peritoneal macrophages of wild-type and TLR4-deficient mice, whereas neither TNF- α nor NO $_2^-$ was produced in those of TLR2- and MyD88-deficient mice (Fig. 24A and B). Similar results were obtained with S-MALP-2 as well (Fig. 24C and D). Further, it has been confirmed that peritoneal macrophages of TLR2- and MyD88-deficient mice were unresponsive to R-MALP-2-or S-MALP-2-stimulated IL-6 production (data not shown). Thus indicates that a lipoprotein/lipopeptide derived from mycoplasma, such as R-MALP-2 or the like, activates macrophages via TLR2 and MyD88.

Example 17 (lipoprotein/lipopeptide-stimulated in vitro kinase assay and Western blot analysis)

[0108] In order to examine whether a lipoprotein/lipopeptide activates intracellular signaling molecules with the results of example 16, peritoneal macrophages of the 4 kinds of mouse (1×10^6) were stimulated with 0.3 ng/ml of R-MALP-2 for 10 minutes, and in vitro kinase assay (Auto in Fig. 25A), Western blot analysis (WB in Fig. 25A), electrophoretic mobility shift assay (Fig. 25B) were conducted with anti-IRAK antibody as in example 12. In addition, in vitro kinase assay (Auto in Fig. 25C) and Western blot analysis (WB in Fig. 25C) with anti-JNK1 antibody were also conducted. As a result, activation of IRAK, NF- κ B and JNK in response to MALP could not confirmed in macrophages of TLR2 and MyD88 knockout mice. These results indicate that the lipoprotein/lipopeptide derived from mycoplasma causes vital reaction via TLR2 and MyD88 signaling pathway.

Industrial Applicability

[0109] The MyD88 knockout mouse, which is used as a bacterial cell component-unresponsive model animal in the present invention, is unresponsive to endotoxin derived from Gram-negative bacteria, peptidoglycan derived from Gram-positive bacteria, lipoteichoic acid, mycobacterium tuberculosis lysate and other such cell wall components of Gram-positive bacteria, a lipoprotein/lipopeptide and the like. Therefore, by using this knockout mouse, it becomes possible to obtain useful information of signaling receptors of selective components such as peptidoglycan which is a cell wall component of Gram-positive bacteria, a lipoprotein/lipopeptide and the like, to conduct screenings of a promoter or a suppressor of bacterial infection, a promoter or a suppressor of responsiveness to bacterial cell components, to evaluate endotoxin activity, IL-1 activity and IL-18 activity in subject materials, and to detect bacterial cell components in subject materials, and consequently, it becomes possible to obtain useful information for development of medicines for diseases caused by excessive production of bacterial cell wall components such as endotoxin and the like, IL-1, IL-18 or receptors of these materials and the like, and for elucidating molecular mechanism in a process of infection by bacteria such as Mycoplasma, Spirochaeta and the like, and for development of new remedies for infections.

Claims

1. The use of a non-human animal whose function of MyD88 gene is deficient on its chromosome as a model animal unresponsive to bacterial cell wall components.
2. The use according to claim 1, wherein the non-human animal is a rodent.
3. The use according to claim 2, wherein the non-human animal is a mouse.
4. The use of a macrophage or splenocyte cell derived from a non-human animal as defined in any of claims 1 to 3 as a model cell unresponsive to bacterial cell wall components.
5. The use according to any preceding claim, to elucidate the action mechanisms of bacterial cell components.
6. The use according to any of claims 1 to 4, to obtain information of signalling receptors of bacterial cell wall components.
7. The use according to any of claims 1 to 4, in a method of detecting bacterial cell components, which method comprises the steps of: (i) administering the subject material to a) an animal or cell as defined in any of claims 1 to 4 and b) to a wild-type non-human animal or cell and (ii) assessing and comparing responsiveness to the subject material.
8. The use according to any of claims 1 to 4, to obtain information for development of medicines for diseases caused by excessive production of bacterial cell wall components.
9. The use according to any preceding claim, wherein the bacterial cell wall component is a lipoprotein/lipopeptide.
10. The use according to claim 9, wherein the lipoprotein/lipopeptide is derived from cell components of bacteria which belong to Mycoplasma, Spirochaeta or Escherichia.
11. The use according to any of claims 1 to 8, wherein the bacterial cell wall component is a peptidoglycan.

EP 1 716 752 B1

12. The use according to any of claims 1 to 8, wherein the bacterial cell wall component is an endotoxin.
13. The use according to any of claims 1 to 8, wherein the bacterial cell wall component is lipotechoic acid.
- 5 14. The use according to any of claims 1 to 8, wherein the bacterial cell wall component is Mycobacterium tuberculosis lysate.
15. The use according to any of claims 1 to 4, to establish a treatment method for endotoxin shock.
- 10 16. The use according to any of claims 1 to 4, to elucidate the molecular mechanism in a process of infection by bacteria to the cell wall components of which the animal is unresponsive.
17. The use according to any of claims 1 to 4, to develop new remedies for infection by bacteria to the cell wall components of which the animal is unresponsive.
- 15

Patentansprüche

- 20 1. Verwendung eines Tiers, das kein Mensch ist und das hinsichtlich der Funktion des MyD88-Gens auf seinem Chromosom defizient ist, als ein Modelltier, welches nicht auf Komponenten der Bakterienzellwand reagiert.
2. Verwendung nach Anspruch 1, wobei das Tier, das kein Mensch ist, ein Nagetier ist.
- 25 3. Verwendung nach Anspruch 2, wobei das Tier, das kein Mensch ist, eine Maus ist.
4. Verwendung einer Makrophagen- oder Splenozytzelle, abgeleitet von einem Tier, das kein Mensch ist, wie es in einem der Ansprüche 1 bis 3 definiert ist, als eine Modellzelle, die nicht auf Komponenten der Bakterienzellwand reagiert.
- 30 5. Verwendung nach einem der vorangegangenen Ansprüche, um die Wirkmechanismen von Komponenten von Bakterienzellen zu erklären.
6. Verwendung nach einem der Ansprüche 1 bis 4, um Informationen über Signalgebungsrezeptor von Komponenten der Bakterienzellwand zu erhalten.
- 35 7. Verwendung nach einem der Ansprüche 1 bis 4 in einem Verfahren zum Detektieren von Komponenten von Bakterienzellen, welches die Stufen umfaßt, bei denen man: (i) das Subjektmaterial a) einem Tier oder einer Zelle, wie in einem der Ansprüche 1 bis 4 definiert, und b) einem Wildtyp-Tier, das kein Mensch ist, oder Zelle verabreicht, und (ii) das Ansprechen auf das Subjektmaterial feststellt und vergleicht.
- 40 8. Verwendung nach einem der Ansprüche 1 bis 4, um Informationen für die Entwicklung von Medikamenten für Erkrankungen zu erhalten, die durch die übermäßige Produktion von Komponenten der Bakterienzellwand verursacht werden.
- 45 9. Verwendung nach einem der vorangegangenen Ansprüche, wobei die Komponente der Bakterienzellwand ein Lipoprotein/Lipopeptid ist.
10. Verwendung nach Anspruch 9, wobei das Lipoprotein/Lipopeptid von Zellkomponenten von Bakterien abgeleitet ist, die zu Mycoplasmen, Spirochaeta oder Escherichia gehören.
- 50 11. Verwendung nach einem der Ansprüche 1 bis 8, wobei die Komponente der Bakterienzellwand ein Peptidoglycan ist.
12. Verwendung nach einem der Ansprüche 1 bis 8, wobei die Komponente der Bakterienzellwand ein Endotoxin ist.
- 55 13. Verwendung nach einem der Ansprüche 1 bis 8, wobei die Komponente der Bakterienzellwand Lipoteichonsäure ist.
14. Verwendung nach einem der Ansprüche 1 bis 8, wobei die Komponente der Bakterienzellwand Mycobacterium tuberculosis-Lysat ist.

EP 1 716 752 B1

15. Verwendung nach einem der Ansprüche 1 bis 4, um ein Behandlungsverfahren für Endotoxinschock zu etablieren.
16. Verwendung nach einem der Ansprüche 1 bis 4, um den molekularen Mechanismus bei einem Verlauf einer Infektion durch Bakterien zu den Zellwandkomponenten, auf welche das Tier nicht reagiert, aufzuklären.
17. Verwendung nach einem der Ansprüche 1 bis 4, um neue Medikamente gegen eine Infektion durch Bakterien zu den Zellwandkomponenten, auf welche das Tier nicht reagiert, zu entwickeln.

5

10 **Revendications**

1. Utilisation d'un animal non humain dont la fonction du gène MyD88 est déficiente sur son chromosome, en tant que modèle ne répondant pas aux composants de paroi cellulaire bactérienne.
- 15 2. Utilisation selon la revendication 1, dans laquelle l'animal non humain est un rongeur.
3. Utilisation selon la revendication 2, dans laquelle l'animal non humain est une souris.
- 20 4. Utilisation d'une cellule de macrophage ou de splénocyte dérivée d'un animal non humain tel que défini dans l'une quelconque des revendications 1 à 3 en tant que cellule modèle ne répondant pas aux composants de paroi cellulaire bactérienne.
- 25 5. Utilisation selon l'une quelconque des revendications précédentes, pour élucider les mécanismes d'action des composants cellulaires bactériens.
- 30 6. Utilisation selon l'une quelconque des revendications 1 à 4, pour obtenir des informations des récepteurs de signalisation des composants de paroi cellulaire bactérienne.
- 35 7. Utilisation selon l'une quelconque des revendications 1 à 4, dans un procédé de détection de composants cellulaires bactériens, ledit procédé comprenant les étapes consistant à : (i) administrer le matériau en question à a) un animal ou une cellule tel(le) que défini(e) dans l'une quelconque des revendications 1 à 4 et b) à un animal non humain ou une cellule non humaine de type sauvage et (ii) évaluer et comparer la réactivité au matériau en question.
- 40 8. Utilisation selon l'une quelconque des revendications 1 à 4, pour obtenir des informations pour le développement de médicaments contre les maladies provoquées par une production excessive de composants de paroi cellulaire bactérienne.
- 45 9. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le composant de paroi cellulaire bactérienne est une lipoprotéine/un lipopeptide.
- 50 10. Utilisation selon la revendication 9, dans laquelle la lipoprotéine/le lipopeptide est dérivé(e) de composants cellulaires de bactéries qui appartiennent aux mycoplasmes, spirochètes ou *Escherichia*.
- 55 11. Utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle le composant de paroi cellulaire bactérienne est un peptidoglycane.
12. Utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle le composant de paroi cellulaire bactérienne est une endotoxine.
13. Utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle le composant de paroi cellulaire bactérienne est un acide lipotéichoïque.
14. Utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle le composant de paroi cellulaire bactérienne est un lysat de *Mycobacterium tuberculosis*.
15. Utilisation selon l'une quelconque des revendications 1 à 4, pour établir un procédé de traitement du choc endotoxique.

EP 1 716 752 B1

16. Utilisation selon l'une quelconque des revendications 1 à 4, pour élucider le mécanisme moléculaire dans un processus d'infection par des bactéries aux composants de paroi cellulaire auxquels l'animal ne répond pas.
17. Utilisation selon l'une quelconque des revendications 1 à 4, pour développer de nouveaux remèdes contre une infection par des bactéries aux composants de paroi cellulaire auxquels l'animal ne répond pas.

5

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7





FIG. 8





FIG. 9




FIG. 10




FIG. 11




FIG. 12





FIG. 13




FIG. 14




FIG. 15





FIG. 16




FIG. 17





FIG. 18

A



B




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24





FIG. 25



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- *Cell*, 1988, vol. 52, 269-279 [0007]
- *Annu. Rev. Cell Dev. Biol.*, 1996, vol. 12, 393-416 [0007] [0007]
- *Cell*, 1996, vol. 86, 973-983 [0007]
- *Nature*, 1991, vol. 351, 355-356 [0007]
- *J. Leukoc. Biol.*, 1998, vol. 63, 650-657 [0007]
- *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 14614-14619 [0007]
- *EMBO J.*, 1997, vol. 16, 6120-6130 [0007]
- *Curr. Opin. Immunol.*, 1999, vol. 11, 13-18 [0007]
- *Nature*, 1997, vol. 388, 394-397 [0008]
- *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 588-593 [0008]
- *Blood*, 1998, vol. 91, 4020-4027 [0008]
- *Gene*, 1999, vol. 231, 59-65 [0008]
- *J. Exp. Med.*, 1998, vol. 187, 2097-2101 [0008] [0100]
- *Mol. Cell*, 1998, vol. 2, 253-258 [0008] [0100]
- *Immunity*, 1999, vol. 11, 115-122 [0008] [0100] [0100]
- *Cell*, 1997, vol. 91, 295-298 [0008] [0009]
- *Adv. Immunol.*, 1979, vol. 28, 293-450 [0009]
- *Annu. Rev. Immunol.*, 1995, vol. 13, 437-457 [0009] [0009]
- *Science*, 1990, vol. 249, 1431-1433 [0009]
- *J. Exp. Med.*, 1998, vol. 188, 2091-2097 [0010]
- *Nature*, 1998, vol. 395, 284-288 [0010]
- *J. Immunol.*, 1999, vol. 163, 639-643 [0010]
- *Science*, 1998, vol. 282, 2085-2088 [0010]
- *J. Exp. Med.*, 1999, vol. 189, 615-625 [0010] [0062]
- *J. Immunol.*, 1999, vol. 162, 3749-3752 [0011] [0062] [0062] [0062]
- *J. Immunol.*, 1999, vol. 162, 6971-6975 [0011] [0012]
- *J. Biol. Chem.*, 1999, vol. 274, 10689-10692 [0011]
- *J. Biol. Chem.*, 1999, vol. 274, 17406-17409 [0012] [0012]
- *J. Immunol.*, 1999, vol. 163, 1-5 [0012] [0012]
- *J. Exp. Med.*, 1997, vol. 185, 1951 [0013]
- *Science*, 1999, vol. 285, 736-739 [0014]
- *Science*, 1999, vol. 285, 732-736 [0014]
- *Infect. Immun.*, 1998, vol. 66, 1638-1647 [0014]
- *Science*, 1998, vol. 282, 2085-8 [0062]
- *FEBS Lett.*, 1994, vol. 332, 197-201 [0063]
- *J. Immunol.*, 1997, vol. 158, 4430-6 [0073]
- *J. Immunol.*, 1995, vol. 155, 2620-30 [0077]
- *Infect. Immun.*, 1994, vol. 62, 2715-21 [0077] [0079]
- *J. Immunol.*, 1992, vol. 149, 541-7 [0081]
- *J. Clin. Invest.*, 1993, vol. 91, 2076-83 [0081]
- *Immunity*, 1998, vol. 9, 143-150 [0087] [0102]
- *Biken J.*, 1975, vol. 18, 77-92 [0095]
- *Infect. Immun.*, 1982, vol. 38, 817-824 [0095]
- *Infect. Immun.*, 1992, vol. 60, 3664-3672 [0097]
- *Immunity*, 1994, vol. 1, 509-516 [0097]
- *J. Biol. Chem.*, 1996, vol. 271, 23310-23316 [0097]
- *Infect. Immun.*, 1996, vol. 64, 1906-1912 [0097]
- *Biochem. Biophys. Res. Commun.*, 1998, vol. 234, 183-196 [0100]
- *Int. J. Peptide Protein. Res.*, 1991, vol. 38, 545 [0103]